Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy with or without autologous DC-CIK immunotherapy for gynecologic cancers
ChiCTR-TRC-14004847Phase 2Recruiting
- Sponsor
- Zhengzhou University
- Start
- Sep 2014
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous cytokine-induced killer cell therapy in Cervical Cancer (CC) and ovarian cancer (2 arms), sponsored by Zhengzhou University. Primary endpoints: Subsets of lymphocytes in peripheral blood mononuclear cells, Regulatory T cells in peripheral blood mononuclear cells and 4 more. Started Sep 2014; status: recruiting.
02
Drugs
autologous cytokine-induced killer cell therapy
03
Conditions
Cervical Cancer (CC)ovarian cancer
Beyond the preview
Go deeper on ChiCTR-TRC-14004847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004847.